Shopping Cart
- Remove All
- Your shopping cart is currently empty
LY3200882 is a highly selective inhibitor of TGF-β receptor type 1 (TGFβRI).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $39 | In Stock | |
5 mg | $89 | In Stock | |
10 mg | $147 | In Stock | |
25 mg | $289 | In Stock | |
50 mg | $455 | In Stock | |
100 mg | $689 | In Stock |
Description | LY3200882 is a highly selective inhibitor of TGF-β receptor type 1 (TGFβRI). |
Targets&IC50 | TGFβRI:38.2 nM (IC50) |
In vitro | LY3200882 effectively inhibits TGFβ-mediated SMAD phosphorylation in tumor and immune cells in vitro, demonstrates anti-metastatic activity in migration assays, and rescues TGFβ1 or T regulatory cell-suppressed naive T cell activity, restoring proliferation in immune suppression assays [1]. |
In vivo | LY3200882 potently inhibits TGFβ mediated SMAD phosphorylation in vivo in subcutaneous tumors in a dose-dependent fashion. LY3200882 has shown anti-metastatic activity in vivo in an experimental metastasis tumor model (intravenous EMT6-LM2 model of triple negative breast cancer) [1]. |
Molecular Weight | 435.52 |
Formula | C24H29N5O3 |
Cas No. | 1898283-02-7 |
Smiles | CC(C)(O)c1cc(Nc2cc(Oc3cn(nc3C3CCOCC3)C3CC3)ccn2)ccn1 |
Relative Density. | 1.36 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
Solubility Information | DMSO: 4.36 mg/mL (10 mM), Sonication is recommended. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.